Tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs

Certain carbohydrate antigens of malignantly transformed cells have been identified as markers for the onset of cancer and have become targets for the development of anticancer vaccine therapies. For tumor antigens, many carbohydrate antigens belong to T-independent (TI) antigens. Carbohydrate conjugated to protein carriers can switch TI antigen to a T-dependent (TD) antigen. Attempts to add an innate immune response element (such as Toll-like receptor ligand) to carbohydrate TI-antigens have also been studied. Glycosylation inhibitors or small interfering RNA have also been used for antitumor and/or antiviral agents. This review aims at describing the vast spectrum of tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs.

[1]  C. Leclerc,et al.  Tn Glycosylation of the MUC6 Protein Modulates Its Immunogenicity and Promotes the Induction of Th17-biased T Cell Responses* , 2010, The Journal of Biological Chemistry.

[2]  R. Dwek,et al.  Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. , 2008, Anti-cancer agents in medicinal chemistry.

[3]  T. Seyfried,et al.  N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours , 2001, British Journal of Cancer.

[4]  J. Taylor‐Papadimitriou,et al.  The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer* , 2006, Journal of Biological Chemistry.

[5]  T. Honjo,et al.  Molecular mechanism of class switch recombination: linkage with somatic hypermutation. , 2002, Annual review of immunology.

[6]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[7]  J. Wolchok,et al.  Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. , 2006, The Journal of clinical investigation.

[8]  M. Frank,et al.  Comprehensive modeling and functional analysis of Toll‐like receptor ligand‐recognition domains , 2010, Protein science : a publication of the Protein Society.

[9]  M. Wolfert,et al.  Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.

[10]  Lai-Xi Wang,et al.  Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. , 2006, Bioconjugate chemistry.

[11]  Xiao-lian Zhang,et al.  Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages1 , 2008, The Journal of Immunology.

[12]  W. Engström,et al.  The effects of glycosylation inhibitors on the proliferation of a Wilms tumour cell line. , 2000, Anticancer research.

[13]  Qian Wan,et al.  From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. , 2009, Journal of the American Chemical Society.

[14]  P. Linton,et al.  Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged , 2009, Cancer Immunology, Immunotherapy.

[15]  T. Oyama,et al.  Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence , 2004, British Journal of Cancer.

[16]  C. Leclerc,et al.  A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. , 1999, Cancer research.

[17]  T. Gallagher,et al.  Action of a library of O-glycosylation inhibitors on the growth of human colorectal cancer cells in culture. , 2005, Biochemical Society transactions.

[18]  G. Boons,et al.  Immunotherapy for cancer: synthetic carbohydrate-based vaccines. , 2009, Chemical communications.

[19]  R. Tiwari,et al.  Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions. , 2009, Glycobiology.

[20]  T. Michaelsen,et al.  The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis , 2004, Scandinavian journal of immunology.

[21]  Kate Rittenhouse-Olson,et al.  Cancer vaccines and carbohydrate epitopes. , 2011, Vaccine.

[22]  Ingo Müller,et al.  Dendritic cells: functional aspects of glycosylation and lectins. , 2009, Human immunology.

[23]  M. Pierce,et al.  Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. , 2009, Glycobiology.

[24]  A. Hoffmann‐Röder,et al.  Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues. , 2010, Chemistry.

[25]  Lai-Xi Wang,et al.  Enhanced immune recognition of cryptic glycan markers in human tumors. , 2009, Cancer research.

[26]  A. Dalgleish,et al.  Overview of Tumor Cell–Based Vaccines , 2006, International reviews of immunology.

[27]  G. Springer.  Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy , 1997, Journal of Molecular Medicine.

[28]  C. Leclerc,et al.  Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. , 2010, Blood.

[29]  S. Danishefsky,et al.  Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience , 2009, Expert review of vaccines.

[30]  Christopher Jones,et al.  Vaccines based on the cell surface carbohydrates of pathogenic bacteria. , 2005, Anais da Academia Brasileira de Ciencias.

[31]  A. Passaniti,et al.  The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth , 1995 .

[32]  P. Vogel,et al.  Glycosidase inhibitors as potential HIV entry inhibitors? , 2004, Current drug metabolism.

[33]  R. Dwek,et al.  Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. , 1995, Virology.

[34]  D. Godson,et al.  The effectiveness and limitations of immune memory: understanding protective immune responses. , 2003, International journal for parasitology.

[35]  D. Bundle.  A carbohydrate vaccine exceeds the sum of its parts. , 2007, Nature chemical biology.

[36]  G. Boons,et al.  The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. , 2004, Chemistry.

[37]  O. Finn,et al.  Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells , 1996, Glycoconjugate Journal.

[38]  D. Hicks,et al.  Prospects in NSAID-derived chemoprevention of colorectal cancer. , 2005, Biochemical Society transactions.

[39]  Lai-Xi Wang,et al.  Antibody recognition of a unique tumor-specific glycopeptide antigen , 2010, Proceedings of the National Academy of Sciences.

[40]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[41]  E. Fischer,et al.  NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses , 2010, Yeast.

[42]  D. Weiner,et al.  Priming characteristics of peptide mimotopes of carbohydrate antigens. , 2003, Vaccine.

[43]  Pin Wang,et al.  Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells , 2011, Journal of biological engineering.

[44]  F. Auzanneau,et al.  Synthesis of a BSA-Le(x) glycoconjugate and recognition of Le(x) analogues by the anti-Le(x) monoclonal antibody SH1: the identification of a non-cross reactive analogue. , 2010, Bioorganic & medicinal chemistry.

[45]  R. Weichselbaum,et al.  MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. , 2009, Cancer research.

[46]  Mahadeo A. Sukhai,et al.  Suppression of Cancer Progression by MGAT1 shRNA Knockdown , 2012, PloS one.

[47]  P. Altevogt,et al.  Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. , 2006, International journal of oncology.

[48]  S. Turanli,et al.  Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[49]  M. Dwek,et al.  Cell surface glycan-lectin interactions in tumor metastasis. , 2011, Acta histochemica.

[50]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.